CITIUS ONCOLOGY INC
CTORNASDAQ🏆 #3286 by market capUS Equity
$918.84▼ $21.50 (−2.34%)
Simulated price1h—
24h▼ 2.3%
7d—
14d—
30d—
1y—
🏦Market Cap
$68M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
49
Weak
No chart data available for CTOR.
Trading Snapshot
- Day Range
- $909.13 – $923.59
- 52-Week Range
- $0.49 – $2.25
- Volume
- $2.42B
- Avg Volume
- $1.91B
- Shares Outstanding
- 93.0M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $28M
- Last Q Revenue
- $7M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.47
- Dividend Yield
- —
Why Investors Own CTOR
- ✓High-growth profile — revenue up +20.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$28M▲ +18.1% YoY
Gross Margin (TTM)
76.4%▲ +3.9% YoY
Operating Income (TTM)
$9M▲ +18.1% YoY
Free Cash Flow (TTM)
$3M▲ +18.1% YoY
About CITIUS ONCOLOGY INC
A company profile for CITIUS ONCOLOGY INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
49/100
Analyst Price Target
ⓘAverage Target
$1,150.31
▲ +25.2% Upside
High Target$1,418.24
Low Target$976.47
Based on 13 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
CITIUS ONCOLOGY INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift CTOR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
CITIUS ONCOLOGY INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.